EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study

Einav Koren, Adar Yaacov, Jamal Zidan, Laila C Roisman, Nir Peled, Noam Asna

Journal of Clinical Medicine · 18.06.2026 · 15 (12) · 4757

DOI: 10.3390/jcm15124757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.06.2026. Verfasst von Einav Koren und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clalit Health Services, Tel Aviv 6209804, Israel. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pembrolizumab-based therapy is a standard first-line option for advanced non-small-cell lung cancer (NSCLC), yet pivotal clinical-trial populations may not reflect patients encountered in routine practice. Real-world cohorts enriched for Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2 and high metastatic burden remain underreported. We assessed real-world outcomes of first-line pembrolizumab in a heterogeneous cohort enriched for these.

Methods

Retrospective cohort analysis of 45 patients with advanced NSCLC who received first-line pembrolizumab-based therapy (monotherapy or with platinum-based chemotherapy) at a single health maintenance organization in Israel between September 2017 and April 2020.

Results

Mean age was 69.3 years (SD 9.0), 82.2% were male, 91.1% were current or former smokers, 37.8% had ECOG PS ≥2 (including 17.8% with ECOG ≥3), and 53.3% had three or more metastatic organ sites. PD-L1 expression was ≥50% in 46.7%, 1–49% in 13.3%, and

Schlagwörter

Stichwörter der Autor:innen

Cox regressionPD-L1immunotherapynon-small-cell lung canceroverall survivalpembrolizumabprogression-free survivalreal-world evidence

Autor:innen und Institutionen

  • Clalit Health Services, Tel Aviv 6209804, Israel.
  • Helmsley Cancer Center, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
  • Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
  • The Oncology Department, Ziv Medical Center, and the Azrieli Faculty of Medicine, Bar-Ilan University, Zefat 1311502, Israel.
  • Cancer Research Institute, Samson Assuta Hospital, Ashdod 7747629, Israel.
  • Faculty of Health Sciences-Microbiology and Immunology, Ben Gurion University, Beer Sheva 8410501, Israel.

Zitieren

APA

Koren, E., Yaacov, A., Zidan, J., C Roisman, L., Peled, N., & Asna, N. (2026). Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study. Journal of Clinical Medicine, 15(12), 4757. https://doi.org/10.3390/jcm15124757

Vancouver

Koren E, Yaacov A, Zidan J, C Roisman L, Peled N, Asna N. Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study. Journal of Clinical Medicine. 2026;15(12):4757. doi:10.3390/jcm15124757

BibTeX
@article{Koren2026,
  author = {Koren, Einav and Yaacov, Adar and Zidan, Jamal and C Roisman, Laila and Peled, Nir and Asna, Noam},
  title = {Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {12},
  pages = {4757},
  doi = {10.3390/jcm15124757}
}
Kostenlos starten →